39503-58-7Relevant academic research and scientific papers
HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS
-
Paragraph 0109; 0110; 0170; 0171, (2018/08/03)
The present technology provides compounds according to Formula (I) as well as compositions including such compounds useful for the treatment of cancers such as non-small cell lung cancer, bladder cancer, or colon cancer.
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
-
Paragraph 0892, (2018/05/24)
The present invention provides compounds, compositions thereof, and methods of using the same.
Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors
Lovering, Frank,Morgan, Paul,Allais, Christophe,Aulabaugh, Ann,Brodfuehrer, Joanne,Chang, Jeanne,Coe, Jotham,Ding, WeiDong,Dowty, Heather,Fleming, Margaret,Frisbie, Richard,Guzova, Julia,Hepworth, David,Jasti, Jayasankar,Kortum, Steve,Kurumbail, Ravi,Mohan, Shashi,Papaioannou, Nikolaos,Strohbach, Joseph W.,Vincent, Fabien,Lee, Katherine,Zapf, Christoph W.
, p. 606 - 621 (2018/01/19)
Many diseases are believed to be driven by pathological levels of reactive oxygen species (ROS) and oxidative stress has long been recognized as a driver for inflammatory disorders. Apoptosis signal-regulating kinase 1 (ASK1) has been reported to be activ
2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS
-
Page/Page column 39, (2012/03/26)
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.
Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds
Beaulieu, Pierre L.,Gillard, James,Bykowski, Darren,Brochu, Christian,Dansereau, Nathalie,Duceppe, Jean-Simon,Hache, Bruno,Jakalian, Araz,Lagace, Lisette,LaPlante, Steven,McKercher, Ginette,Moreau, Elaine,Perreault, Stephane,Stammers, Timothy,Thauvette, Louise,Warrington, Jeff,Kukolj, George
, p. 4987 - 4993 (2007/10/03)
Benzimidazole-based allosteric inhibitors of the hepatitis C virus (HCV) NS5B polymerase were diversified to a variety of topologically related scaffolds. Replacement of the polar benzimidazole core by lipophilic indoles led to inhibitors with improved potency in the cell-based subgenomic HCV replicon system. Transposing the indole scaffold into a previously described series of benzimidazole-tryptophan amides generated the most potent inhibitors of HCV RNA replication in cell culture reported to date in this series (EC50 ～ 50 nM).
INHIBITORS OF PAPILLOMA VIRUS
-
Page 47-49, (2008/06/13)
The use of a compound of formula (II): or its enantiomers or diastereoisomers thereof, or salts or pharmaceutically-acceptable esters thereof, in the treatment or prevention of a papilloma virus infection, particularly human papilloma virus in a mammal, wherein R11; X4; X5; X6; R13; R14; W; Z; Y; T; and R18 are defined herein. The present invention also provides novel compounds, pharmaceutical compositions and methods for using these compounds and compositions in the treatment or prevention of papilloma virus infection. More particularly, the present invention provides compounds, compositions and methods for inhibiting papilloma virus DNA replication by interfering with the E1-E2 protein-protein interaction essential for viral DNA replication.
VIRAL POLYMERASE INHIBITORS
-
Page 158, (2010/02/07)
An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula (I): wherein wherein A, B, R2, R3, L, M1, M2, M3, M4, Y1, Y0, Z and Sp are as defined in claim 1, or a salt thereof, as an inhibitor of HCV NS5B polymerase.
